Great news from Neuro Event Labs Oy, as Nelli®, their AI-powered seizure detection and characterization…
Continue Reading-
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic…
Continue Reading -
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on…
Continue Reading -
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878
Transition into clinical-stage development marks a significant corporate and R&D milestone. Munich, Germany, October 17,…
Continue Reading -
Alex Therapeutics has signed an exclusive agreement with Navamedic
Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion…
Continue Reading -
SCIRHOM
SciRhom GmbH is a German biotechnology company...
Continue Reading -
Attgeno announces positive results from Supernitro Phase II study
Attgeno AB today announces positive data from the company’s Phase IIa study, evaluating the effects…
Continue Reading -
Oncoinvent Receives FDA Fast Track Designation for Radspherin®
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian…
Continue Reading -
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease Bagsværd, Denmark, and…
Continue Reading -
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa...
Continue Reading